Eosinophilic Granulomatosis With Polyangiitis
2
Pipeline Programs
4
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 4 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
ViiV HealthcareNC - Durham
2 programs1
DepemokimabPhase 3Monoclonal Antibody
Longitudinal Study for Eosinophilic Granulomatosis With PolyangiitisN/A
GSKLONDON, United Kingdom
1 programLongitudinal Study for Eosinophilic Granulomatosis With PolyangiitisN/A1 trial
Active Trials
AstraZenecaCAMBRIDGE, United Kingdom
1 programLongitudinal Study for Eosinophilic Granulomatosis With PolyangiitisN/A
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Nippon ShinyakuNS-229
GSKLongitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
Clinical Trials (2)
Total enrollment: 745 patients across 2 trials
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
Start: Dec 2023Est. completion: Jul 202645 patients
Phase 2Recruiting
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
Start: Apr 2006Est. completion: Dec 2028700 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 745 patients
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.